Member Info for CrustyPete

And what proportion of the company too? Would floating, say, 20% of Scancell pass muster?

On the topic of a Nasdaq listing, does anyone know if , and if so, what is the minimum size for a Nasdaq IPO? I wonder what Scancell would have to include in any float in order to reach that valuation. For example, would GT alone be sufficient? Or might it not need SCOPE to be included?

A Nasdaq listing may trigger a rerate but surely would enable Scancell to do what their advisers have long suggested which is to "go it alone" and thereby, perhaps, and depending on the size of the raise, reduce the likelihood or the need of a sale or partnership? Of course it may only be a "back-up" option but unlikely that the Company would have need for both a Nasdaq flotation and a partnership for US SCOPE trials? Though as shareholders I am sure that longer term we would likely be better rewarded taking 1SCIB and iSCIB1+ to monetisation/ production independently, albeit that such a payoff would be a longer wait.

EE's earlier thought about Floating GT on Nasdaq would be a better compromise, raising through the sale of GT (longer dev journey and possibly "non-core") whilst allowing shareholders to get full value from SCOPE and, later, MODI.

Similar on linkedin:

https://www.linkedin.com/company/aminex-plc/posts/

Aminex Executive Chairman Charles Santos draws on three decades of energy diplomacy - from the TAPI pipeline to East Africa - to argue that diversification must be restored as the organising principle of energy policy. Read the full piece in the latest edition of Modern Diplomacy: https://lnkd.in/enzunF-7

The views expressed are those of Charles Santos in a personal capacity.

Yes makes sense EE, thanks.

That would be a good option.

Agreed EE but floating GT on Nasdaq in itself would do little for funding SCOPE trials - surely that raise would be ringfenced for GT funding? If so we would still need a second funding option for SCOPE methinks?

The obvious downside of any NASDAQ listing is that it would, by its very nature, involve a sizeable dilution of UK shareholders. Not necessarily a bad thing but worth considering even so.

So if they are looking at a Nasdaq listing, how far down the road has this progressed? Or is the answer "not at all"; whilst Seth was in "residence"?

Agreed re the price fall Jbatch and with their holding another 19 million the risk of further disposals going forward methinks..... sale at CAN$ 2.45 or £1.38 so hopefully not until the sp reaches those levels again.

On another point. It seems highly unusual and unlikely for the CFO of a Listed company to be exiting with only one months notice. I cannot believe that he was not, contractually, required to give a lot more than that. So has this been on the cards for months or have they chosen to foreshorten?

It will be interesting to see what the market reaction to this news is. Positive or negative? Personally I am happy to see the apparent commitment to a Nasdaq listing; as phoenixs says, it should lead to a rerating. On the downside it will take a good deal of time to execute and H2 is not too far away.

Whatever the speculation, without positive news on funding of the next SCOPE trial post FDA approval this is only going one way. My purchase from Monday looks like a mistake in retrospect. Trading is mostly on the sell side which that says it all, the ME has got bugger all to do with that. Voilindog's reservations about "funding" may well be not too far from the mark, unfortunately.

We need news and soon.

Your guess is as good as mine littlered.... a volatile stock with restricted liquidity and few Marker Makers, it doesn't take much. A big tree shake ahead of today's Investor event perhaps? As someone said earlier there are a lot of people holding good profits here and no-one likes to see them eroded, so a big tree shake often loosens people's resolve.

Gap filling? Well it went up 30+% from these levels over 36 hours so it could easily do so again. Though I am happy that I took profit yesterday and now have my free carry,

Indeed RP and I could see either or both of SCOPE and MDI finding a suitor, or suitors, collectively or individually. But would a full sale compromise the Genmab deal? Possibly so and hence perhaps the reason that GT was set up; to hold that IP (and deal) separate from Scancell "TopCo".

Blubay, you say "they haven’t yet proved it can be done commercially. ". The BoD certainly haven't come out and stated that it is "commercial" but nor have they officially stated that it isn't. The GWR at ITM1 wasn't what they had hoped, it seems and hence they are looking at a potentially more attractive or efficient model at the next well BUT there is still the possibility that having found the optimal GWR elsewhere they could still tie ITM1 into any processing/ production facility. As long as the Helium extracted would more than cover its own costs, why not?

And yet SCIB1 and iSCIB1+ are both more advanced in trial and approval terms than either Modi and any of the antibody products. Are those antibody "solutions" really at a stage where they are "saleable"? Looking at recent "deals" maybe so but surely SCOPE offers the greatest opportunity to crystalise optimal value? That said Genmab might have seen sufficient progress to allow them to want to take control of further development.

I think you are probably right GainsOnly but the percentage gains are, surely, now more limited with some downside risk now too and there are other opportunities with greater upside (in my opinion of course).

Yes, happy to admit that I top sliced yesterday at 136p and now have "free carry". Thankfully didn't need to sell very many!

Let's just hope that, if so, the RNS provides a little more information and context to this update, otherwise I cannot see it making any difference to the sp or market sentiment.

Yes I take your point Voilindog but I fully expect them to get another milestone payment in the next two months (three max), which would further extend that "runway". Of course I may be wrong and it could be that uncertainty that has been depressing the sp but that is just as likely to be the influence of those external factors that we all know about.